Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Inserm.

    Client Virtual Booth

    INSERM

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Inserm
    France Flag
    Country
    Country
    France
    Address
    Address
    101, rue de Tolbiac Paris, 13 75013, FR
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.inserm.fr/en/home/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/inserm
    Twitter
    Twitter
    https://twitter.com/inserm_en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    T.H.A.C Announces the Acquisition of an International Patent on Its Drug Candidate ALF-5755 For the Early Treatment of Type 2 Diabetes Mellitus and Rela...

    Details:

    This acquisition strengthens the protection and the potential of the First in Class drug candidate of T.H.A.C which incorporates the active ingredient ALF-5755 for the treatment of Type 2 Diabetes Mellitus and severe complications.


    Lead Product(s): ALF-5755

    Therapeutic Area: Endocrinology Product Name: ALF-5755

    Highest Development Status: Phase IProduct Type: Large molecule

    Partner/Sponsor/Collaborator: T.H.A.C.

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition September 27, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Solidarity Therapeutics Trial Produces Conclusive Evidence on the Effectiveness of Repurposed Drugs for COVID-19 in Record Time

    Details:

    Interim data from the WHO-coordinated Solidarity Therapeutics Trial suggest that remdesivir, hydroxychloroquine, lopinavir / ritonavir, and interferon regimens in COVID patients have little or no impact on 28-day mortality or the in-hospital course of COVID-19.


    Lead Product(s): Remdesivir,Lopinavir,Hydroxychloroquine Sulphate

    Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: World Health Organization

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 15, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-2024-05-06

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search